IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of New York

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

New York  $ 48,158,586.22
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
22nd Century Limited, LLC X-22 Prescription Smoking Cessation Aid $ 20,939.50 $ 223,539.75
AccuVein, LLC Development of Light Reflective Vein Visualization Device - AV300 $ 244,479.25  
Adarza Biosystems, Inc. Novel Molecular Profiling Tool for Diagnosing, Guiding Therapy and Reducing Cancer Costs. $ 169,837.27 $ 74,641.98
Advance Biofactures Corporation Collagenase for Tissue Dissociation-New Cellular Therapies $ 51,186.62 $ 130,736.83
Advance Biofactures Corporation The use of Collagenase Therapy in the Treatment of Human Lipoma $ 51,138.20 $ 193,341.05
Advanced BioMedical Technologies Inc. Bio-degradable Polymer Orthopedic Internal Fixation Devices $ 196,382.50 $ 48,096.75
Advanced Monitoring Caregiving, Inc Development of an Interactive Voice Rdsponse Clinical Application $ 244,479.25  
Advanced Monitoring Caregiving, Inc. Development of a Predictive Model for Assessing Telehealth Impactability $ 47,306.00 $ 74,189.50
Advanced Monitoring Caregiving, Inc. Integration of a Clinical Televideo Solution into a Web-Based Telehealth Software Application $ 23,750.00 $ 112,199.00
Aggamin Pharmaceutics LLC Novel therapy for the treatment of preeclampsia in pregnant women   $ 244,479.24
Ambulatory Monitoring Inc Develpoment of a Compact, High-Performance Wrist-Worn Motionlogger Actigraph Device $ 151,083.00 $ 93,396.25
ANDROBIOSYS, INC PROSTATE DISEASE TREATMENT $ 166,822.00 $ 77,657.25
Angioblast Systems Inc Allogeneic Adult Stem Cells to Treat and Reverse Wet Age Related Macular Degeneration $ 200,149.50 $ 44,329.74
Angioblast Systems Inc Allogenic Adult Stem Cells to Treat Reverse Congestive Heart Failure $ 244,479.24  
Angioblast Systems Inc Adult Stem Cells to  Treat Type 2 Diabetes by regenerating Beta Islet Cells $ 237,301.00 $ 7,178.24
Angioblast Systems Inc Allogenic Adult Stem Cells for the Treatment of Acute Myocardial Infarction (AMI) $ 237,509.50 $ 6,969.74
Angioblast Systems Inc Cord Blood Expanded by Allogeneic Adult Stem Cells to Treat Hematologic Malignancies $ 244,479.24  
Angion Biomedica Corp 4 Phenylphtalazione, other projects: BB3, Ang797, Rec1, Dual Kinase, Atra $ 244,479.24  
Angion Biomedica Corporation Rac1, $ 2,374.99 $ 56,433.08
Angion Biomedica Corporation BB3 Other projects: Ang797, Rac1, Dual Kinase, Atra, 4-Phenylphalazionone $ 244,479.24  
Angion Biomedica Corporation Dual Kinase, Other Projects: BB3, Rac1, Atra, Ang797, 4 Phenylphthalazinone   $ 61,001.01
Angion Biomedica Corporation ATRA, Other Projects: BB3, Ang797, Rac1, Dual Kinase, 4 Phenylphthalazinone   $ 30,785.58
Angion Biomedica Corporation ANG-797, Other Projects: BB3, Rac 1, Dual Kinase, Atra, 4 Phenylphthalazinone $ 16,966.56  
Anterios, Inc (formerly known as Encapsion, Inc) New Treatments for Hyperhidrosis and Acne $ 244,479.24  
Apath LLC Research and Development Tools for the Treatment of Viral Infections $ 244,479.25  
Apath, LLC Drug Discovery:  Specific and broad spectrum antivirals $ 244,479.25  
AptaMatrix, Inc. New diagnostics for epigenetic disorders with applications to mental health diseases   $ 87,981.00
AptaMatrix, Inc. New diagnostics for thrombosis, bleeding disorders, and proliferatives diseases $ 244,479.25  
Archer Biosciences Inc TPI-287, a novel anti-microtuble agent for the Treatment of Cancer $ 244,479.25  
Ariston Pharmaceuticals, Inc. AST-726 for the treatment of Vitamin B-12 Deficiency   $ 244,479.25
Aureon Laboratories, Inc Prognostic Model for Active Surveillance in Prostate Cancer Patients $ 244,479.24  
Avatar Medical, LLC Dityrosine (DT) stabilization of an HIV-1 Env vaccine immunogen $ 53,960.00 $ 190,519.25
Biomedica Management Corporation Hemostatic Agent for use in non-compressible hemorrhage $ 183,491.99 $ 60,987.26
Biomerix Corporation therapeutic Devices Using the Novel Biomerix Biomaterial $ 244,479.25  
BIO-SIGNAL GROUP CORP Putting EEG in the Emergency Department $ 51,605.84 $ 192,873.40
Bio-Signal Group Corp The Home Epilepsy Monitoring Unit $ 190,184.75 $ 54,294.49
BIOSOF LLC IMPROVED MANUSCRIPT SEARCH THROUGH PUBSEQ $ 19,981.50 $ 34,272.00
BioSource Pharm, Inc. Design and Synthesis of Novel Antibiotics Against Resistant Gram Positive Bacteria $ 61,791.50 $ 182,687.75
Buffalo Biolabs LLC Development of Dual Cargo Liposomes Containing Cytoxiz Drugs and Reversan $ 44,955.82 $ 97,977.53
Celmatix, Inc. FertilArray: In Vitro Diagnostic for Oocyte (Egg) Quality and Female Infertility $ 16,125.00 $ 228,354.25
Celtic Pharma Development Services America Inc Xercept $ 244,479.25  
Celtic Pharma Development Services America, Inc. TDT 067 $ 244,479.25  
Cerebral Assessment Systems Inc Cognivue Development $ 244,479.25  
CEROVENE INC New Dosage Latform Project $ 138,050.50 $ 106,428.74
Chembio Diagnostic System Inc DPP Multiplex Rapid Test for Detection of HIV P24 Antigen & HIV 1/2 Antibodies $ 51,575.50 $ 192,903.75
Chembio Diagnostic Systems , Inc DPP® Multiplex Rapid Test for Detection of Antibodies to Hep-C & HIV1/2 $ 118,840.00 $ 125,639.25
Chembio Diagnostic Systems Inc Sure-Check Unitized Home Use Finger-stick Whole Blood Rapid HIV 1/2 Test   $ 244,479.25
Chembio Diagnostic Systems, Inc. DPP® Rapid Test for the Detection of Antibodies to Hepatitis-C $ 71,649.50 $ 172,829.75
Chembio Diagnostic Systems, Inc. DPP® Rapid Test for Detection of Antibodies to HIV1/2 in Oral Fluid $ 233,578.00 $ 10,901.25
Chembio Diagnostic Systems, Inc. DPP ® Multiplex Rapid Test for Diagnosing Active, Untreated Syphilis $ 144,961.50 $ 99,517.75
Cleveland BioLabs Inc Protectan CBLB502 $ 244,479.24  
Codevax Vaccine against Respiratory Syncytial Virus (RSV) $ 2,500.00 $ 18,500.00
Codevax Anti-Autolysin Passive Immunity for MRSA Osteomyelitis $ 30,426.50 $ 60,250.00
Coronado Biosciences CNDO102 for Treatment of Cancer $ 244,479.25  
Coronado Biosciences CNDO101 for Treatment of Cancer $ 244,479.25  
Coronado Biosciences C1 for Treatment of Cancer $ 244,479.25  
Critical Care Diagnostics, Inc. sST2 Guided Personalized Management of Cardiovascular Disease and Cancer Treatment $ 244,479.25  
Curemark LLC CM-AT Therapeutic FDA authorized Phase III clinical trials for the treatment of autism $ 244,479.25  
Cynvec LLC CYN 101 onvolytic vector for the diagnosis and treatment of cancer $ 244,479.25  
Delcath Systems, Inc Delcath Chemosaturation System $ 244,479.25  
Diffinity Genomics, Inc. Enhanced Genetic Sample Analyst and Use $ 174,809.78 $ 69,669.47
Dipexium Pharmaceuticals, LLC Pexiganan cream for treatment of diabetic foot infection (DFI)   $ 244,479.24
Durata Therapeutics, Inc. Dalbavancin $ 244,479.25  
Egenix, Inc Chemically-distinct low molecular weight compounds against validated cancer targets $ 244,479.24  
ELLIQUENCE, LLC RD-ELL 10-1003   $ 197,000.00
Empire Genomics LLC Non-invasive Bladder Cancer Molecular Diagnostic test.   $ 244,479.25
Endocrine Technology, L.L.C. ET002 Therapy of Colon Cancer $ 244,479.24  
EpiCept Corporation Crolibulin novel small molecule vascular disruption agent for the treatment of solid tumors $ 244,479.25  
EpiCept Corporation NP-1 is a novel approach in the management of pain associated with neuropathies. $ 244,479.25  
EpiCept Corporation Ceplene, Immunotherapy for remission maintenance in AML $ 244,479.25  
ET Neuron Inc ETN 002: Therapy of Amyotrophic Lateral Sclerosis (ALS) $ 244,479.24  
ET Neuron Inc ETN 001: Therapy of Alzheimer's Disease $ 244,479.24  
ET Transplant, Inc. ETR 001: Therapeutic Project for Renal Transplant Tolerance $ 244,479.24  
ETVaccine Technology, Inc. ETV003: Factor H binding Meningococcal Vaccine $ 244,479.24  
Evidence-Based Solutions, Inc Evidence-Based Diagnostic Device/Solution $ 244,479.24  
Exosome Diagnostics Inc Diagnosis of Cancer, Staging and Patient Stratification from Exosome Content Analysis $ 244,479.25  
Fonar Corporation Fonar Upright MRI Diagnostic Technology $ 244,479.25  
Foresight Biotherapeutics Inc FST-200, a novel Otic Suspension for the Treatment of Acute Otitis $ 244,479.25  
Foresight Biotherapeutics Inc FST-100, a Novel Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis $ 244,479.25  
Garnett McKeen Laboratory, Inc. Novel Organo-Metallic Compounds in the Treatment of Cancer $ 244,479.25  
Garnett McKeen Laboratory, Inc. Palladium-Lipoic Acid Formulation in the Treatment of Brain Cancer $ 7,500.00 $ 95,000.00
Glycobia, Inc. Manufacturing Therapeutic Glycoproteins in E. Coli $ 52,269.43 $ 139,127.56
iCardiac Technologies, Inc. Diagnosing Acute Coronary Syndrome in patients with Chest Pain $ 23,465.50  
ImaCor Inc TEE Monitoring for Intensive Care $ 244,479.25  
Immco Diagnostics, Inc. Autoimmune Disease Markers   $ 65,480.00
IMMCO DIAGNOSTICS, INC. DETECTION OF CHRONIC SINUS   $ 44,705.00
Immune Pharmaceuticals Corp Therapeutic monoclonal antibody drug for the treatment of IBD and Severe Asthma $ 125,000.00 $ 119,479.25
Immune Pharmaceuticals Corporation Monoclonal antibody for the treatment of the treatment of Graft versus Host Disease (GVHD) $ 50,000.00 $ 194,479.25
Immune Pharmaceuticals Corporation Therapuetic Targeting Cancer Stem Cells $ 237,500.00 $ 6,979.25
Immune Pharmaceuticals Corporation BI-specific anitbodies for the treatment of fatal Chronic Lymphocytic Leukemia (CLL) $ 225,000.00 $ 19,479.25
Impulse Dynamics USA, Inc Optimizer III System (medical device) for Treatment of Chronic Heart Failure (CHF) $ 244,479.25  
Incuron LLC Development of Curaxins as novel anticancer agents   $ 244,479.25
INSPIRION DELIVERY TECHNOLOGIES LLC ABUSE DETERENT OPIOIDS $ 244,479.24  
Integrated Nano-Technologies, LLC An Automated Point-of-Care Molecular Diagnostic System $ 244,479.25  
Intercept Pharmaceuticals INT-747 $ 244,479.25  
INTERCEPT PHARMACEUTICALS INT-777 $ 244,479.25  
Intra-Cellular Therapies, Inc ITI-007 for the treatment of insomnia and sleep disorders $ 244,479.25  
Intra-Cellular Therapies, Inc ITI-007 for the treatment of Schizophrenia and Depression $ 244,479.25  
Intra-Cellular Therapies, Inc. ITIPDE1 $ 244,479.25  
Intra-Cellullar Therapies, Inc PET Ligands $ 166,269.00 $ 78,210.25
IRX Therapeutics Inc IRX-2 Patented novel biologic to treat newly-diagnosed advanced head and neck cancer $ 244,479.24  
IRX Therapeutics, Inc Skin Test:  Patented novel diagnostic device to determine immune competency. $ 12,136.14 $ 96,923.56
IRX Therapeutics, Inc. IRX-4: Patented novel therapeutic cancer vaccine to treat prostate and brain cancer $ 244,479.25  
IRX Therapeutics, Inc. IRX-2 Patented novel therapeutic vaccine to treat HPV infected women $ 244,479.25  
IRX Therapeutics, Inc. MIMP: Patented novel small molecule to restore immune protection against influenza A virus $ 26,118.23 $ 218,361.02
Isoflux Inc Drug Delivery from Nanoporous Inorganic Structures $ 124,861.14 $ 119,618.10
JARVIK HEART, INC Development & Clinical Trials of Highly Miniaturized Heart Assist Therapeutics $ 244,479.25  
Kadmon Corporation LLC Targeted therapy for treatment of advanced gastric cancer   $ 244,479.24
Karos Pharmaceuticals, Inc. Novel tryptophan hydroxylase 1 (TPH1) inhibitors   $ 244,479.25
Keryx Biopharmaceuticals, Inc Perifosine $ 244,479.24  
Keryx Biopharmaceuticals, Inc. Zerenex (ferric citrate) $ 244,479.25  
Kinentia Biosciences LLC Flt-3 Kinase Inhibitor Program $ 1,641.50 $ 3,724.50
Kinentia Biosciences, LLC Mu Opioid Moderator Program $ 1,928.50 $ 10,323.50
KINEX PAHRMACEUTICALS KX01 $ 244,479.24  
KINEX PHARMACEUTICALS, LLC KX03 $ 244,479.24  
KINEX PHARMACEUTICALS, LLC KX02 $ 244,479.24  
Kite Pharma, Inc. Development of Adv-GM-CAIX: A Novel Immunotherapy for the Treatment of Cancer $ 23,027.14 $ 221,452.10
Lambda Max, LLC Electrical Inhibition of Human Preterm Uterine Contractions $ 2,605.00 $ 179,976.00
LighTouch Medical Inc Non-Invasive Platform Technology for The Molecular Analysis of Blood Analytes $ 205,000.00 $ 39,479.25
Litron Laboratories Ltd Development of a Novel method for quantifying splenic function $ 7,170.50 $ 6,032.00
Lixte Biotechnology Holdings Inc LB-1 an inhibitor of protein phosphatase 2A is a novel effective anticancer drug $ 127,994.00 $ 116,485.25
Lucid Inc VivaScope Confocal Imaging for the early detection of Melanoma and other skin cancers $ 244,479.25  
Lumetrics Inc Portable Fundus Camera $ 13,119.10 $ 71,223.75
Medicon Inc. A novel agent for colon cancer prevention $ 7,722.00 $ 236,757.24
Mela Sciences Inc MelaFind $ 244,479.25  
Misonix Inc. Sonatherm 600i System $ 74,283.50 $ 40,107.00
Myeloma Health LLC Gene Expression Profiles (GEPs) for the Effective Treatment of Multiple Myeloma (MM) $ 12,786.00 $ 231,693.25
MyoCardioCare Inc Development of mechanical cardiac and circulatory support device for cardiac arrest patients $ 164,982.41 $ 79,496.84
NaniRx Therapeutics Inc Breast Cancer Precision Immune Stimulants (PINS) $ 244,479.24  
Natrogen Therapeutics International, Inc Development of new drug (Natura-alpha) for treating autoimmune diseases $ 244,479.24  
Neogenix Oncology Inc Advancing Two Novel Biomarkers for Diagnosing Pancreatic and Colorectal Cancers. $ 244,479.25  
Neogenix Oncology, Inc Development of h16C3 mAb as a Novel Treatment for Colorectal, Pancreatic & Lung Cancers $ 244,479.25  
Neogenix Oncology, Inc NPC-1C (ensituximab) as a Target Therapy for Pancreatic and Colorectal Cancers $ 244,479.24  
Nex Genix Pharmaceuticals Holdings Inc NX101 Novel Non-Surgical Treatment for Dermal Neurofibromas $ 35,292.76 $ 204,382.47
NexGenix Pharmaceuticals Holdings Inc Hsp90 Inhibitors for Glioma and Other Primary Tumors of the Central Nervous System (CNS) $ 244,479.25  
NexGenix Pharmaceuticals Holdings, Inc Hsp90Inhibitors for Neurodegenerative Diseases $ 244,479.25  
NexGenix Pharmaceuticals Holdings, Inc Hsp90 Inhibitors for Solid Tumors including Refractory Tumors with Brain Metastases $ 91,940.11 $ 152,539.14
Nomir Medical Technologies Inc Antimirobial resistance reversal and bio-burden reduction of bacterial and fungal pathogens $ 244,479.25  
NovaSterilis Inc. Terminal Sterilization of Allograft Tissue $ 37,866.00 $ 170,050.00
Nutrition 21, Inc. Cr-enhanced insulin for the treatment of type 1 and type 2 diabetes $ 4,350.00 $ 100,000.00
Ohr Pharmaceutical, Inc. OHR/AVR118 for Cachexia $ 65,121.68 $ 179,357.56
ONY Inc. Testing an Aerosol System fo Lung Surfactant Delivery   $ 40,000.00
Oratel Diagnostics LLC Saliva assay for endometriosis $ 43,298.00 $ 85,500.00
Ort, Inc F/K/A Oncology Research Therapeutics, Inc Clinical study to demonstrate the use of in-vitro chemofit assay $ 21,679.50  
Orthocon Inc The ORTHOstat-L project $ 244,479.25  
Oxyvita, Inc. OxyVita® $ 244,479.25  
Palyon Corporation Paylon Implantable Drug Delivery System (IDDS) $ 244,479.25  
Penwest Pharmaceuticals Co A0001, a coenzyme Q analog for treatment of mitochondrial diseases $ 244,479.25  
PERICOR THERAPEUTICS, INC GP-531 AS A TREATMENT FOR ACUTE HEART FAILURE $ 244,479.25  
Pharmadva, LLC Automatic Home Medication Dispenser (AHMD)   $ 244,479.25
PharmaNova Inc PN 200: A New Topical Treatment for Genital Herpes $ 63,611.94 $ 180,867.31
PharmaNova Inc PN203: Targeted Nanoparticles for Oncology Medicines $ 60,893.93 $ 183,585.32
PharmaNova, Inc Implantable, refillable, reprogrammable, rechargeable drug delivery device $ 17,852.88 $ 37,451.00
PharmaNova, Inc. AP022 A New Topical Treatment for Glaucoma $ 28,100.12 $ 92,274.00
Pneuma Pharmaceuticals Inc Calfactant for Acute Respiratory Distress Syndrome (CARDS study) $ 244,479.25  
Population Diagnostics Inc A rational & systematic approach to parkinson's disease ("PD") drug therapy development   $ 244,479.25
Population Diagnostics Inc Development of an Autism early Detection Genetic Test   $ 244,479.25
Primros Therapeutics, Inc XL647 PKD Therapeutic   $ 244,479.24
Progenics Pharmaceuticals Inc PSMA ADC $ 244,479.24  
PROGENICS PHARMACEUTICALS, INC PRO 140 $ 244,479.24  
PROGENICS PHARMACEUTICALS, INC. HCV ENTRY INHIBITOR $ 244,479.24  
PsychoGenics Inc Clinical Development of Eltoprazine $ 244,479.24  
PsychoGenics Inc. Discovery and development of Adenosine $ 244,479.24  
PsychoGenics Inc. Partnered Drug Discovery $ 244,479.25  
PsychoGenics Inc. Discovery and Development of Peptides for CNS Disorders $ 244,479.24  
PsychoGenics Inc. Development of Novel Nicotinics for Treatment of Resistant Depression $ 244,479.24  
Pulmokine, Inc A PDGFR inhibitor for the treatment of pulmonary arterial hypertension   $ 134,390.00
Pulmokine, Inc. A novel JAK inhibitor for the treatment of pulmonary arterial hypertension   $ 115,043.00
Recor Medical Inc Therapeutic Ultrasound For The Treatment Of Mitral Regurgitation $ 244,479.24  
Redox Pharmaceutical Corporation Doxovir ™ ("Doxovir") $ 244,479.25  
Remedy Pharmaceuticals Inc Development of intravenous glyburide to treat acute ischemic stroke $ 244,479.24  
Remedy Pharmaceuticals Inc Development of intravenous glyburide to treat acute spinal cord injury $ 244,479.24  
Remedy Pharmaceuticals, Inc IV glyburide to reduce edema and steroid use and improve outcomes following brain tumor surgery $ 244,479.24  
Sarentis Therapeutics, Inc. Neurotensin pain medication $ 69,755.00 $ 174,724.25
Sarentis Therapeutics, Inc. Silk Corneal Inlay (herein "Silk Film")   $ 244,479.25
Savvipharm Inc Development of a Safer Version of Doxorubicin to Diminish Cardiotoxicy in Cancer Patients $ 56,069.00 $ 188,410.24
Scientific Optics, Inc Development of Specialized Contact Lens for Dyslexic and Macular Degeneration Patients $ 83,956.02 $ 93,870.62
Senex Biotechnology, Inc Drugs inhibiting damage response mechanism of cancer, Alzheimer's and viral diseases. $ 219,179.20 $ 25,300.04
Serometrix LLC Drug targeting Androgen receptor DNA binding to block progression of prostate cancer $ 68,115.00 $ 176,364.25
Serometrix LLC Peptimer Drugs That Inhibit Binding of PCSK9 to LDLR to lower Blood Cholesterol $ 40,146.00 $ 119,593.00
Sherrington Pharmaceuticals Inc Resiniferatoxin (RTX)   $ 244,479.25
SIGA Technologies, Inc Development of Arenavirus Antivirals $ 109,775.00 $ 87,503.50
SIGA Technologies, Inc. ST-246 Orthopoxvirus Antiviral Program $ 244,479.24  
SIGA TECHNOLOGIES, INC. DENGUE ANTIVIRAL DEVELOPMENT PROGRAM $ 111,466.50 $ 94,596.00
SKS Ocular, LLC A novel dry AMD animal model for drug screening and mechanistic studies   $ 244,479.25
SONOSTICS, INC. ASSESSMENT OF MUSCLE FORCE FOR DIAGNOSIS OF MUSCULOSKELETAL DISEASE $ 169,032.50 $ 75,446.74
Stemline Therapeutics, Inc SL-401 $ 244,479.24  
Synergy Pharmaceuticals Inc Agonists of Guanylate Cyclase-C $ 244,479.24  
T3 Therapeutics LLC Thyroid hormone treatment of Diastolic Heart Failure $ 84,000.00 $ 100,000.00
Tactical Therapeutics Inc Safety of Carboxyamidotriazole orotate in age-related macular degeneration Diabetic Retinopathy   $ 244,479.24
Tactical Therapeutics inc Safety of Carboxyamidotriazole oratate (CTO) in Adult Advanced and Metastatic Cancer Patients as Monotherapy and in Combination with Temozolomide in Patients with Glioblastoma Multiforme in Phase I. $ 244,479.24  
Tactical Therapeutics, Inc Safety of Carboxyamidiotriazole orotate (CTO) in Pediatric Cancer Patients as Monotherapy and in Combination with Temozolomide in Pediatric Patients with Glioblastoma Multiform in Phase 1 $ 100,000.00 $ 144,479.24
Tartis, Inc. Novel Agents for Treatment of Hematological Diseases $ 5,848.47 $ 108,273.03
TechnoVax Inc Development of Virus-Like Particles {VLPs} Influenza Vaccines $ 17,834.00 $ 226,645.24
TechnoVax, Inc Development of Universal Influenza Vaccine using Virus-like Particles (VLP's)   $ 41,800.00
TechnoVax, Inc Development of Universal Virus-Like Particles(VLP) based HIV vaccine   $ 35,150.00
TechnoVax, Inc Development of a Multivalent Dengue Virus-Like Particle (VLP) Vaccine   $ 127,000.00
TechnoVax, Inc. Respiratory Syncytial Virus Vaccine Based on Virus-Like Particles (VLPs)   $ 41,800.00
Tetragenetics, Inc Tetra Express Protein Manufacturing Platform $ 244,479.25  
The SmartPill Corporation SmartPill Wireless Motility Capsule {WMC} $ 244,479.24  
Therasis Inc Therasis Filter $ 190,861.00 $ 53,618.25
Therasource LLC Development of Human AM/AMBP-1 as Critical Care Therapeutics $ 200,076.50 $ 44,402.75
TheraSource LLC Preclinical Development of Alpha2A-Adrenoceptor Antagonist: A Novel Anti-Sepsis Therapy $ 28,583.00 $ 46,404.00
Therex LLC Therapeutics for the prevention and teatment of resistant Staphylococcus aureus infections. $ 108,128.00 $ 42,887.50
Thermal Gradient Inc. Rapid, Portable Molecular Diagnostic System $ 56,152.00 $ 188,327.24
Tracon Pharmaceuticals Inc TRC105 $ 244,479.25  
Tracon Pharmaceuticals Inc  % Paramount Biocapital Inc TRC102 $ 244,479.25  
Tracon Pharmaceuticals, Inc.C/O Paramount Biocapital Inc. TRCO93 $ 236,050.02 $ 8,429.23
Transcendent International LLC Collaborative IVR Platform for Multilingual Patient Outreach and Treatment Adherence (a.k.a VoiceReach) $ 175,725.07 $ 68,754.18
TRANSLUMINAL TECHNOLOGIES LLC VELOX CD   $ 244,479.25
TransTech Systems Inc Non-Invasive Continuous Glucose Monitor for Diabetes $ 45,777.76 $ 83,961.29
Ultradian Diagnostics, LLC Research and Development of a Continuous Glucose Monitoring System $ 134,180.00 $ 110,299.24
United Biomedical, Inc Humanized Antibody [UB-421] Targets HIV Receptor for "Entry Inhibitor" Immunotherapy $ 244,479.25  
United Biomedical, Inc. Preventative AIDS Vaccine by Targeting HIV-1 gp120 $ 96,807.01 $ 147,672.24
United Biomedical, Inc. Alzheimer's Disease Vaccine by Targeting Amyloid-beta Peptide $ 227,385.87 $ 17,093.38
United Biomedical, Inc. HIV Therapeutic Vaccine by Targeting Host Cell HIV Receptor $ 244,479.25  
Vaccinex, Inc VX-35 Project $ 244,479.24  
Vaccinex, Inc. VX-5 Project $ 244,479.24  
Vaccinex, Inc. VX-15 Project $ 244,479.24  
Vitatex Inc Vitatex Functional Cell Adhesin Matrix (fCAM) $ 33,874.61 $ 138,799.28
Vivaldi Biosciences Inc Novel Small-Molecule Antiviral Therapeutics for Influenza $ 145,419.50 $ 99,059.75
Vivaldi Bosciences Inc Live Attenuated Influenza Vaccine (LAIV) for Greater Efficacy in the Elderly $ 244,479.25  
Vybion, Inc. ProCode $ 127,412.00 $ 117,067.24
X-Ray Optical Systems, Inc Body-fluids trace-element analyzer to detect disease and guide therapeutic decisions $ 244,479.25  
Zeomedex, LLC Improving the tolerability of lipase inhibitors   $ 244,479.25

 

Page Last Reviewed or Updated: 04-Jun-2014